We examined retrospectively 44 patients with refractory acute leukemia (acute myeloid leukemia (AML)/acute lymphoblastic leukemia ¼ 25/19) who underwent allogeneic transplantation at our center between 11/1990 and 04/2004. The median leukemic blasts was 25% and age 28 years (range, 3-56). Twenty-one patients had untreated relapse, 13 failed reinduction, eight in partial remission and two aplastic. Conditioning was myeloablative using cyclophosphamide, busulfan, total-body irradiation and etoposide (Bu/Cy/VP, n ¼ 22; TBI/Cy/VP, n ¼ 17; others, n ¼ 5) followed by marrow or peripheral blood transplant (n ¼ 23/21) from unrelated or related donors (n ¼ 28/16). All patients had graft-versus-host disease (GVHD) prophylaxis with cyclosporin and methotrexate. One patient experienced late graft failure. Severe acute-GVHD and chronic-GVHD appeared in eight and 14 patients, respectively. Thirteen patients (30%) remain alive after a median of 25.3 months (range, 2.4-134.1); with 31 deaths, mostly from relapse (n ¼ 15) and infections (n ¼ 12). Overall survival (OS) and progression-free survival (PFS) at 5 years was 28 and 26%, respectively. OS and PFS were significantly better with blasts p20% and time to transplant p1 year while transplant-related mortality was less with the use of TBI. We conclude that patients with refractory leukemia can benefit from allogeneic BMT, especially with p20% marrow blast.
Introduction
Acute leukemias are a heterogeneous group of clonal disorders characterized by proliferation and/or maturation arrest of hematopoietic progenitor cells in the marrow and blood. The management continues to pose a challenge to haemato-oncologists.
Despite intensive remission induction chemotherapy, up to 20-35% of adults (3-17% of children) with acute myeloid leukemia (AML) and 5-10% adults (o5% children) with acute lymphoblastic leukemia are primarily refractory. 1, 2 Of those that achieve a remission, as much as 70-80% fail consolidation largely due to relapse or sustained aplasia. Salvage therapy using further chemotherapy and/or autologous transplantation (with or without purging) though associated with high remission rates, may allow time to find an adequately matching donor. Relapse rates however remain high.
Allogeneic stem-cell transplantation (allo-SCT) remains the only salvage option with curative potentials available, but the long-term benefits of the procedure and whether all patients should benefit from it remains controversial. Rigorous clinical trials are limited by small numbers, ethical limitations, short follow-up periods, heavy pretreatment and poor pretransplant clinical status, and have thus failed to define its role in management (clearly). 3 In the first reported study, Zander et al. 4 described the survival of five of 14 patients with primary refractory leukemia for 3-60 months indicating the possibility of long-term survival (progression-free survival (PFS)) after allo-SCT. Subsequent studies have also confirmed this. [5] [6] [7] However, some recent reviews examining patients with high-risk acute leukemias, including some with refractory leukemias, have noted that majority of these patients have poor outcomes with a relapse rate between 25 and 50%. 8, 9 Relapse, infections and cGVHD rank among the highest cause of treatment failure or death in those patients who survive the immediate transplant period. There is a need to optimize the procedure to build on the gains so far recorded. Increasing strain on the health-financing systems and the attendant reappraisal of the cost-benefit analysis of medical treatment protocols have also contributed to these calls.
We retrospectively examined the factors affecting the outcome of 44 patients with refractory acute leukemia who underwent allo-SCT at our center between 11/1990 and 04/2004.
Patients and methods

Patients
Between November 1990 and April 2004, 44 consecutive patients with refractory acute leukemia (defined as X5% marrow blasts at transplant) received allogeneic donor SCT at the Bone Marrow Transplantation Department, University-Hospital Hamburg, Eppendorf, Germany and results were analyzed as of August 1, 2004 . The characteristics of the patients and transplant are given in Tables 1-3. HLA typing Before 1997, HLA typing of class I was performed by serology only. Later, polymerase chain reaction-based, sequence-specific primer (PCR-SSP), low-resolution typing was used for class I antigens. For HLA class II, genomic high-resolution typing by PCR-SSP or PCR-SSOP (sequence-specific oligonucleotide probes) was used.
Stem cell mobilization
For PBSC mobilization, all donors were treated with granulocyte colony-stimulating factor (G-CSF; Amgen, Thousand Oaks, CA, USA; Rhoˆne-Poulenc Rorer, Lyon, France) for 4-6 days before apheresis. The total daily dose of G-CSF ranged from 9 to 12.5 mg/kg per day, administered subcutaneously once or twice daily.
Conditioning
Preparative regimens consisted, in most patients, of standard myeloablation using a combination of cyclophosphamide (Cy) and etoposide (VP) with either busulfan (Bu; 'Bu/Cy/VP'; n ¼ 22) or total body irradiation ('TBI/Cy/ VP'; n ¼ 17). Cyclophosphamide was given as 60 mg/kg/day intravenously (i. Table 2 .
Immunosuppression
Thirty patients received pre-transplant immunosuppression with antithymocyte globulin (ATG-Fresenius: Fresenius AG, Bad Homburg, Germany) and one had Campath-1H (Medac Schering Onkologie GmbH, Munich, Germany). All but two patients received standard post transplantation immunosuppression comprising short-course methotrexate and cyclosporine-A (mtx, csa; MC). Twelve patients (27%) received only MC. MC was combined with immunoglobulins (MCI; either as Octagam, n ¼ 15; Pentaglobin, n ¼ 5; or unspecified, n ¼ 3) in 23 (52%) other patients. MC was also combined with corticosteroids in three (7%) patients and mycophenolate mofetil in one (2%) patient. Two (5%) and one (2%) patients respectively received, in addition to MCI, mycophenolate mofetil and corticosteroids. Cyclosporine-A, corticosteroids and immunoglobulins were used in two (5%) patients. þ cell count was carried out.
Engraftment
Leukocyte engraftment was defined as the first of 2 consecutive days with a total white cell count (WBC) greater than 1.0 Â 10 9 /l. Platelet engraftment was defined as the first of 3 consecutive days when platelet counts were greater than 20 Â 10 9 /l and satisfied the following conditions: (1) all platelet counts are greater than 20 Â 10 9 /l; (2) no platelet transfusion was given on or between the first and third days of counts; (3) the third platelet count was at least as high as the first; and (4) the three counts were at least 24 h apart. Progressive donor cell engraftment was monitored by different methods of chimerism analysis over time, as described elsewhere.
10-14
Graft-versus-host disease (GVHD) Acute GVHD (aGVHD) was graded 0-4 according to standard criteria. 15 Chronic GVHD (cGVHD) was assessed in patients surviving more than 100 days after transplantation and was defined as limited or extensive. 16 Statistics Event-related data were measured from the date of transplantation to that of disease progression or death from any cause (in the case of PFS), of death from any cause (in case of OS), and of transplant procedure-related death (in the case of TRM). On the date of last follow-up in patients without the respective event, the data were censored.
Survival functions were estimated by the Kaplan-Meier method and compared by the log-rank test (univariate) and by the Cox proportional hazards model (multivariate). Results of univariate comparisons were considered significant at a P-value o0.05 but for multivariate analysis, all univariate comparisons with Po0.1 were included in the Cox models. All statistical analyses were performed using Microsoft Excel, WinSTAT Statistics for Windows (for univariate) while WiSP GmbH, Germany carried out the multivariate analysis.
Results
Engraftment
All 40 patients surviving more than 21 days achieved leukocyte engraftment at a median of 16 days (range, 10-26 days). Thirty-five patients achieved platelet engraftment at a median of 23 days (range, 14-40 days) and the other nine had relapses or died before achieving this end point. One patient however had graft failure at day 154 and eventually died of sepsis.
Acute and chronic GVHD Grades 1-2/3-4 aGVHD appeared in 13/8 (30/18%) patients at a median of 30 days (range, . Of all patients that survived beyond day 100, 14 (32%) developed cGVHD at a median of 171 days (range, 100-730). One of the 13 deaths before day 100 was attributed to aGVHD.
Overall survival
After an overall median follow-up of 25 months (range, 2.4-134.1) post transplant, 13 patients (30%) were alive; 31 having been lost to relapse (n ¼ 15), infections (n ¼ 12), multiorgan failure (n ¼ 2), regimen-related toxicity (n ¼ 1); the cause being unclear in one case. Univariate KaplanMeier analyses of OS, PFS, TRM and RFS are shown in Table 4 . The Kaplan-Meier probability of OS projected to 1 and 5 years post transplant was 32 and 28% ( Figure 1) .
Univariate analyses showed OS to be significantly affected by time from diagnosis to transplant (Figure 2) , percentage blasts at the time of transplant (Figure 3 ), patients' CMV status and ABO blood-group mismatch. However, multivariate analyses (Table 5) , only confirmed a significant difference in the OS of the 16 patients who had blasts p20% at the time of transplant when compared to the 26 who had 420% blasts (HR: 3.22; P ¼ 0.0084); and also when the 26 patients whose time to transplant was less than 1 year was compared to the 18 transplanted after 1 year of diagnosis (OS; HR: 2.44; P ¼ 0.023).
Transplant-related mortality TRM at 100 days and 1 year post transplant is 22 and 37%, respectively. Univariate analyses identified patients' CMV status, donors' sex, donors' age and the use of TBI-based conditioning as factors with positive impact. Further analysis showed that TRM was significantly less with the use of TBI (HR: 0.14; P ¼ 0.012), but higher when the donor was 450 years old (HR: 4.82; P ¼ 0.024).
Progression-free survival
Kaplan-Meier probability of PFS at 5 years is 26%. Initial analysis of the factors affecting the PFS showed a trend towards significance in the percentage blasts at the time of transplant, time to transplant and ABO blood-group Relapse-free survival Kaplan-Meier probability of RFS at 5 years is 45%. There is a trend towards significance in the RFS of patients who received stem cells from related as compared to unrelated donors, which was not sustained on multivariate analysis.
Discussion
We have shown that allogeneic stem cell transplantation can induce long-term disease remission and possibly cure some patients with refractory acute leukemia using standard myeloablative conditioning regimens. It is clear that patients with o20% blasts, who come to transplant within 1 year of diagnosis or are conditioned with a TBIbased regimen have significantly better outcomes. It thus appears possible to define a subclass of patients who require more than the 'standard' conditioning if we are to achieve results comparable to those in standard-risk patients.
It is conceivable that a high proportion of blasts presents a larger tumor load and increases the chances of multidrugresistant (MDR) colonies developing, whose activities go unchecked in a T cell-poor host and whose proliferative potentials are not easily matched by a population of new stem cells. [17] [18] [19] It is however interesting that the outcomes are relatively unchanged with blast counts up to 20% when compared to those with 5% or less blasts. This argues in favor of further attempts at blast reduction in patients with high blast counts, which inevitably lengthen time to transplant. It can also be argued that this result lends some credence to the new recommendations for the definition of acute leukemia and suggests some prognostic relevance. 20, 21 Radiochemotherapy, in an attempt to reduce total systemic exposure or escalated conditioning, may well be an attractive option here. Patients coming to BMT in postinduction marrow aplasia traditionally do very poorly because of increased risks of severe life-threatening fungal and/or bacterial infections. Two of our patients were aplastic; one died at day 115 of fungal infection while the other survived for 43 years and died of relapse. Some studies have suggested nonmyeloablative regimens for this subclass. [22] [23] [24] The small number of patients definitely makes some strong conclusions difficult at this stage but it would be interesting to see what happens with increasing numbers and longer follow-up. Refractory patients transplanted after 1 year of diagnosis may have more advanced diseases but are also likely to have been exposed to more radiochemotherapies which may compromise their ability to withstand conditioning. These patients also tend to have higher incidences of fungal infections and mucositis. 25, 26 A very recent study has suggested that delays in securing a matched donor may be circumvented if enhanced GVHD prophylaxis (albeit, without ex vivo T cell depletion) is offered and a haplo-identical-related donor is used without increasing the outcomes of acute or chronic GVHD. 27 Satisfactory antileukemic effects have long been described for TBI, in combination with piperazinedione, in adults with primary refractory acute leukemia in a series of reports. 4, [28] [29] [30] [31] [32] However, at that time the authors made no claims for the regimen because of the paucity of data on alternative regimens. Mengarelli et al. 8 in their recent study noted that the 'alternative regimens' used in refractory acute leukemia did not improve the outcome profiles for these patients. In this small study, it is interesting to note that of the 13 surviving patients; five have survived 41400 days, and all had TBI-based conditioning. Further work is needed to define the optimal conditioning strategy in these group of patients and determine the long-term outcomes of such regimens with a view to improve on the present results.
